Response Expands Lung Cancer Offerings with OHSU's NGS Test | GenomeWeb

NEW YORK (GenomeWeb) ─ Response Genetics entered the next-generation sequencing-based diagnostics market this week with the launch of a non-small cell lung cancer panel proprietary to the Knight Diagnostic Laboratories at Oregon Health & Science University.

The test, according to OHSU's website, operates on an Ion Torrent PGM platform and gauges a number of genetic alterations known to impact lung cancer patients' response to different treatments, as well as markers that are being studied in investigational drug trials.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.